Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines

Maurizio Viale, Ilaria Pastrone, Caterina Pellecchia, Maria O. Vannozzi, Sergio Cafaggi, Mauro Esposito

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

DPR, cis-diamminechloro-[2-(diethylamino)ethyl 4-aminobenzoate, N4]-chlorideplatinum(II) monohydrochloride monohydrate, is a newly developed water-soluble platinum compound which posses minimal cross-resistance to cisplatin and shows relatively less side effects. In an attempt to establish whether the combination of DPR with other conventional anticancer drugs would be of any benefit we assessed in vitro the cytotoxic effects of combinations of DPR with the antimetabolites 5-fluorouracil (5-FU) and methotrexate (MTX), the alkylating agents mitomycin C (MMC) and cisplatin, the antimicrotubule agent taxol (TAX), and the intercalating agent of the anthracycline group doxorubicin (DOX) on murine M5076 ovarian reticulosarcoma and human A2780 ovarian carcinoma cells. These agents were selected because of their common use in the clinic and because they represent four distinct categories of antineoplastic mechanisms. Cells were incubated for 72 h in the presence of single or combined drugs, and the cytotoxic effect was determined by the MTT assay. The analysis of combination treatment was made by the isobole method. In human A2780 cells, an overall synergy was found for DPR combined with 5-FU, DOX and cisplatin. Synergistic effects were also observed for most combinations with MTX or MMC. A DPR concentration-dependent additivity and antagonism was seen at the highest MTX concentration (1 μM), while additive effects were observed for the combined treatments of DPR and low concentrations of MMC (0.008 and 0.0016 μM) Additive effects were also observed for the association of DPR and TAX over most combinations tested. In murine M5076 cells, synergism was the prevailing result observed when DPR was combined with 5-FU, DOX, MMC or cisplatin. When administered together with MTX we observed additivity over most combinations tested. These findings suggest that DPR, when simultaneously administered with standard anticancer agents, may be advantagious for cyto-killing.

Original languageEnglish
Pages (from-to)457-463
Number of pages7
JournalAnti-Cancer Drugs
Volume9
Issue number5
DOIs
Publication statusPublished - 1998

Fingerprint

Mitomycin
Methotrexate
Ovarian Neoplasms
Cisplatin
Fluorouracil
Doxorubicin
Cell Line
Paclitaxel
Pharmaceutical Preparations
Antineoplastic Agents
para-Aminobenzoates
Benzocaine
Platinum Compounds
Intercalating Agents
Antimetabolites
Alkylating Agents
Anthracyclines
Non-Hodgkin's Lymphoma
Carcinoma
cisplatin-procaine complex

Keywords

  • Anticancer drugs
  • DPR
  • In vitro assay
  • Synergism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. / Viale, Maurizio; Pastrone, Ilaria; Pellecchia, Caterina; Vannozzi, Maria O.; Cafaggi, Sergio; Esposito, Mauro.

In: Anti-Cancer Drugs, Vol. 9, No. 5, 1998, p. 457-463.

Research output: Contribution to journalArticle

Viale, Maurizio ; Pastrone, Ilaria ; Pellecchia, Caterina ; Vannozzi, Maria O. ; Cafaggi, Sergio ; Esposito, Mauro. / Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. In: Anti-Cancer Drugs. 1998 ; Vol. 9, No. 5. pp. 457-463.
@article{35e87e703acd43248eba864cbfc3f75d,
title = "Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines",
abstract = "DPR, cis-diamminechloro-[2-(diethylamino)ethyl 4-aminobenzoate, N4]-chlorideplatinum(II) monohydrochloride monohydrate, is a newly developed water-soluble platinum compound which posses minimal cross-resistance to cisplatin and shows relatively less side effects. In an attempt to establish whether the combination of DPR with other conventional anticancer drugs would be of any benefit we assessed in vitro the cytotoxic effects of combinations of DPR with the antimetabolites 5-fluorouracil (5-FU) and methotrexate (MTX), the alkylating agents mitomycin C (MMC) and cisplatin, the antimicrotubule agent taxol (TAX), and the intercalating agent of the anthracycline group doxorubicin (DOX) on murine M5076 ovarian reticulosarcoma and human A2780 ovarian carcinoma cells. These agents were selected because of their common use in the clinic and because they represent four distinct categories of antineoplastic mechanisms. Cells were incubated for 72 h in the presence of single or combined drugs, and the cytotoxic effect was determined by the MTT assay. The analysis of combination treatment was made by the isobole method. In human A2780 cells, an overall synergy was found for DPR combined with 5-FU, DOX and cisplatin. Synergistic effects were also observed for most combinations with MTX or MMC. A DPR concentration-dependent additivity and antagonism was seen at the highest MTX concentration (1 μM), while additive effects were observed for the combined treatments of DPR and low concentrations of MMC (0.008 and 0.0016 μM) Additive effects were also observed for the association of DPR and TAX over most combinations tested. In murine M5076 cells, synergism was the prevailing result observed when DPR was combined with 5-FU, DOX, MMC or cisplatin. When administered together with MTX we observed additivity over most combinations tested. These findings suggest that DPR, when simultaneously administered with standard anticancer agents, may be advantagious for cyto-killing.",
keywords = "Anticancer drugs, DPR, In vitro assay, Synergism",
author = "Maurizio Viale and Ilaria Pastrone and Caterina Pellecchia and Vannozzi, {Maria O.} and Sergio Cafaggi and Mauro Esposito",
year = "1998",
doi = "10.1097/00001813-199806000-00013",
language = "English",
volume = "9",
pages = "457--463",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines

AU - Viale, Maurizio

AU - Pastrone, Ilaria

AU - Pellecchia, Caterina

AU - Vannozzi, Maria O.

AU - Cafaggi, Sergio

AU - Esposito, Mauro

PY - 1998

Y1 - 1998

N2 - DPR, cis-diamminechloro-[2-(diethylamino)ethyl 4-aminobenzoate, N4]-chlorideplatinum(II) monohydrochloride monohydrate, is a newly developed water-soluble platinum compound which posses minimal cross-resistance to cisplatin and shows relatively less side effects. In an attempt to establish whether the combination of DPR with other conventional anticancer drugs would be of any benefit we assessed in vitro the cytotoxic effects of combinations of DPR with the antimetabolites 5-fluorouracil (5-FU) and methotrexate (MTX), the alkylating agents mitomycin C (MMC) and cisplatin, the antimicrotubule agent taxol (TAX), and the intercalating agent of the anthracycline group doxorubicin (DOX) on murine M5076 ovarian reticulosarcoma and human A2780 ovarian carcinoma cells. These agents were selected because of their common use in the clinic and because they represent four distinct categories of antineoplastic mechanisms. Cells were incubated for 72 h in the presence of single or combined drugs, and the cytotoxic effect was determined by the MTT assay. The analysis of combination treatment was made by the isobole method. In human A2780 cells, an overall synergy was found for DPR combined with 5-FU, DOX and cisplatin. Synergistic effects were also observed for most combinations with MTX or MMC. A DPR concentration-dependent additivity and antagonism was seen at the highest MTX concentration (1 μM), while additive effects were observed for the combined treatments of DPR and low concentrations of MMC (0.008 and 0.0016 μM) Additive effects were also observed for the association of DPR and TAX over most combinations tested. In murine M5076 cells, synergism was the prevailing result observed when DPR was combined with 5-FU, DOX, MMC or cisplatin. When administered together with MTX we observed additivity over most combinations tested. These findings suggest that DPR, when simultaneously administered with standard anticancer agents, may be advantagious for cyto-killing.

AB - DPR, cis-diamminechloro-[2-(diethylamino)ethyl 4-aminobenzoate, N4]-chlorideplatinum(II) monohydrochloride monohydrate, is a newly developed water-soluble platinum compound which posses minimal cross-resistance to cisplatin and shows relatively less side effects. In an attempt to establish whether the combination of DPR with other conventional anticancer drugs would be of any benefit we assessed in vitro the cytotoxic effects of combinations of DPR with the antimetabolites 5-fluorouracil (5-FU) and methotrexate (MTX), the alkylating agents mitomycin C (MMC) and cisplatin, the antimicrotubule agent taxol (TAX), and the intercalating agent of the anthracycline group doxorubicin (DOX) on murine M5076 ovarian reticulosarcoma and human A2780 ovarian carcinoma cells. These agents were selected because of their common use in the clinic and because they represent four distinct categories of antineoplastic mechanisms. Cells were incubated for 72 h in the presence of single or combined drugs, and the cytotoxic effect was determined by the MTT assay. The analysis of combination treatment was made by the isobole method. In human A2780 cells, an overall synergy was found for DPR combined with 5-FU, DOX and cisplatin. Synergistic effects were also observed for most combinations with MTX or MMC. A DPR concentration-dependent additivity and antagonism was seen at the highest MTX concentration (1 μM), while additive effects were observed for the combined treatments of DPR and low concentrations of MMC (0.008 and 0.0016 μM) Additive effects were also observed for the association of DPR and TAX over most combinations tested. In murine M5076 cells, synergism was the prevailing result observed when DPR was combined with 5-FU, DOX, MMC or cisplatin. When administered together with MTX we observed additivity over most combinations tested. These findings suggest that DPR, when simultaneously administered with standard anticancer agents, may be advantagious for cyto-killing.

KW - Anticancer drugs

KW - DPR

KW - In vitro assay

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=0031846776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031846776&partnerID=8YFLogxK

U2 - 10.1097/00001813-199806000-00013

DO - 10.1097/00001813-199806000-00013

M3 - Article

VL - 9

SP - 457

EP - 463

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -